12-10-2022 03:00 via wallstreet-online.de

Antisense Therapeutics (ANP): Breaking the Mould in DMD treatment

LONDON, UK / ACCESSWIRE / October 11, 2022 / Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a …
Weiterlesen »